Skip to main content
Evidence Snapshot

Substance-P receptor

CHEMBL249 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T21:08:10Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL249
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Substance-P receptor as ChEMBL target CHEMBL249, mapped to UniProt P25103. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Substance-P receptor
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL249
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P25103
Substance-P receptor
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Substance-P receptor matters

As of 2026-09-13

Substance-P receptor is reviewed as Substance-P receptor (UniProt P25103); Substance-P receptor shows approved-linked disease relevance led by Vomiting. 5 more disease programs remain visible in the same review block.; 5 linked drugs keep this evidence frame grounded.; the current evidence base includes 17 approved drugs, 4152 compounds, and 614 assays, with lead potency reaching pChEMBL 11.0.

Disease context
Vomiting

Substance-P receptor shows approved-linked disease relevance led by Vomiting. 5 more disease programs remain visible in the same review block. 5 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include APREPITANT, CASOPITANT, FOSAPREPITANT DIMEGLUMINE.

Start review with Vomiting because it currently carries approved-linked support. Linked drugs include APREPITANT, CASOPITANT, FOSAPREPITANT DIMEGLUMINE, FOSNETUPITANT CHLORIDE HYDROCHLORIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 5 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 17 approved drugs, 4152 compounds, and 614 assays for this target. The dominant activity type is IC50. CHEMBL1270066 is the current potency anchor at pChEMBL 11.0.

Use CHEMBL1270066 as the tractability anchor when discussing potency (pChEMBL 11.0).

Activity source · ChEMBL 36 via Core Engine
17 approved pChEMBL 11.0
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Substance-P receptor matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P25103, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why Vomiting is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

4152
Total Compounds
614
Total Assays
17
Approved Drugs
IC50: 3168.0, KI: 2047.0, EC50: 22.0, KD: 127.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL1270066
 11.0 Ki —
No preferred name
CHEMBL281797
 11.0 IC50 —
No preferred name
CHEMBL26761
 11.0 IC50 —
No preferred name
CHEMBL3215877
 10.9 IC50 —
No preferred name
CHEMBL1214024
 10.9 IC50 —

Approved Drugs

Structure Compound First Approval
ROLAPITANT
CHEMBL3707331
 2015
NETUPITANT
CHEMBL206253
 2014
APREPITANT
CHEMBL1471
 2003
PAROXETINE
CHEMBL490
 1992
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T21:08:10Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL249